PRAX - Praxis Precision Medicines, Inc. Stock Analysis

Stock Taper

OPPORTUNITY RADAR SCREENER COMPARE ANY 2 STOCKS

PRAX

PRAXIS PRECISION MEDICINES, INC.

NASDAQ

$259.86

▼ DOWN 1.40% (-3.69)

KEY STATISTICS

Market Cap$7.35 B

52w High$392.70

52w Low$50.56

Dividend Yield—

Frequency—

P/E-20.10

Volume517.23K

Shares Out.27.88M

COMPANY

LEADERSHIP

CHIEF EXECUTIVE

Marcio Silva De'Souza

COMPENSATION 2026

Salary$659,200

Stock Awards$2,368,125

Incentive Plan Pay$1,483,200

All Other Comp.$506,998

Total$8,708,648

ABOUT

SECTOR

Healthcare

WENT PUBLIC

October 16, 2020

METHOD OF GOING PUBLIC

IPO

FULL TIME EMPLOYEES

168

PRICE TARGET

Target High$1201.00

Target Low$162.00

Target Median$575.00

Target Consensus$603.83

UPCOMING EARNINGS

DateNov 9, 2026

DayMonday

Rev. Est.$130.77K

NOV

MON

SPLIT RECORD

DATE	TYPE	RATIO
2023-11-29	Reverse	1:15

ETFS HOLDING THIS STOCK

ETFS HOLDING

196

LISTED HERE

RANKED BY POSITION SIZE

INSTITUTIONAL OWNERSHIP

SHARES OWNED

64.61%

HOLDERS

373

TOP 8 OF 373 · RANKED BY POSITION SIZE

Janus Henderson Group Plc

Adage Capital Partners Gp, L.L.C.

Perceptive Advisors LLC

2.0M sh

$681.63M

Baker Bros. Advisors LP

1.8M sh

$586.95M

Point72 Asset Management, L.P.

1.5M sh

$79.29M

PRICE

$259.86 ▼ DOWN 1.40% (−$3.69)

OVERLAYS

About Praxis Precision Medicines, Inc.

https://www.praxismedicines.com ↗

Praxis Precision Medicines, a Boston-based clinical-stage biopharma, develops CNS disorder therapies like PRAX-114 and PRAX-944, targeting depression, tremor, epilepsy, and related conditions through innovative drug candidates and collaborations.

INDUSTRY

Biotechnology

A PRODUCT PRAXIS PRECISION MEDICINES, INC. IS KNOWN FOR

Ulixacaltamide

Ulixacaltamide is an investigational oral drug for essential tremor, showing positive Phase 3 results, FDA Breakthrough Therapy Designation, and a submitted NDA as Praxis' most advanced pipeline candidate.

COMPETITORS

COMPETITOR

Praxis Precision Medicines in 2025

SENTIMENT: + POSITIVE

REGULATORY · DECEMBER 2025

Praxis Precision Medicines Receives FDA Breakthrough Therapy Designation for Ulixacaltamide in Essential Tremor

The U.S. Food and Drug Administration (FDA) granted Breakthrough Therapy Designation for ulixacaltamide for the treatment of essential tremor. This designation is intended to expedite the development and review of drugs for serious conditions and was based on positive topline data from the Phase 3 Essential3 program, highlighting the drug's potential to address a significant unmet medical need for the estimated seven million people in the U.S. with this common movement disorder.

LEADERSHIP STRATEGY · JANUARY 2026 · IN PROGRESS

Praxis Fortifies Leadership and Board to Spearhead Transition to Commercial-Stage CNS Company

In a deliberate move to prepare for the potential commercial launch of its late-stage CNS pipeline, Praxis Precision Medicines appointed two new members with extensive global launch and strategic transaction experience to its board and promoted key executives to Chief Operating Officer and President of Research & Development. This strategic overhaul is designed to embed commercial and late-stage development expertise into the company's leadership as it anticipates multiple near-term product launches.

Latest News

GLOBENEWSWIRE · OCT 2, 2026

Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

BOSTON, Oct. 02, 2026 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (Nasdaq: PRAX), a fully integrated, leading central nervous system (CNS) precision neuroscience biopharmaceutical company, today announced that on October 1, 2026, the Compensation Committee of Praxis' Board of Directors granted restricted stock unit awards covering an aggregate of 3,478 shares of its common stock to fourteen new non-executive employees under the Praxis Precision Medicines, Inc. 2024 Inducement Plan (the 2024 Inducement Plan). The restricted stock unit awards were granted as inducements material to the employees' entering into employment with Praxis in accordance with Nasdaq Listing Rule 5635(c)(4).

READ ARTICLE

EARLIER COVERAGE

DEFENSE WORLD · OCT 2, 2026

Reviewing Praxis Precision Medicines (NASDAQ:PRAX) & Actinium Pharmaceuticals (NYSE:ATNM)

Praxis Precision Medicines (NASDAQ: PRAX - Get Free Report) and Actinium Pharmaceuticals (NYSE: ATNM - Get Free Report) are both healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their earnings, analyst recommendations, risk, valuation, institutional ownership, profitability and dividends. Analyst Recommendations This is a summary of

READ ARTICLE